TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By The Schall Law Firm
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against Skye Bioscience for allegedly making false and misleading statements about its drug candidate nimacimab's effectiveness during the period of November 4, 2024 to October 3, 2025.

Insights
GOOG   positive

Part of the $3 trillion market cap club with $3.4 trillion valuation


SKYE   negative

The company is accused of overstating its drug candidate's commercial and clinical prospects, making false public statements that misled investors about nimacimab's effectiveness